Alembic Pharmaceuticals Receives USFDA Approval for Generic Prucalopride Tablets
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its generic prucalopride tablets in 1 mg and 2 mg strengths. These tablets, equivalent to Takeda Pharmaceuticals' Motegrity, are indicated for treating chronic idiopathic constipation in adults. The market for prucalopride tablets is estimated at $100 million for the year ending March 2026, according to IQVIA data.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 38/100.
Outlets measured: businessstandard, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 28 Jul, 10:21 am. Other outlets followed.